摘要:
Described are visible light absorbing compounds. The compounds have a visible light absorption maximum between 430 and 480 nm and a full width half maximum (FWHM) at the visible light absorption maximum of at least 35 nm and up to 150 nanometers, wherein the compounds are photostable. The compounds are also thermally stable. The compounds substantially mimic the visible light absorbance properties of macular pigment while remaining photostable and thermally stable. The compounds may be used in a variety of articles, including ophthalmic devices. Formula (I):
摘要:
Изобретение относится к химии, фармацевтике и медицине, а именно, к новому химическому соединению из класса производных 9-оксоакридинил-10-ацетата: L-лизина 9-оксоакридинил-10-ацетат, которое стимулирует продукцию интерлейкина-24 (IL-24) и фактора некроза опухолей бета (TNF-β), и обладает противоопухолевой активностью. Изобретение может быть использовано в противоопухолевой терапии, в частности, в качестве адъюванта в комплексном лечении онкологических заболеваний. Задачей изобретения является создание нового химического соединения, стимулирующего продукцию цитокинов интерлейкина-24 и фактора некроза опухолей бета и проявляющего противоопухолевую активность при низкой токсичности. Поставленная задача реализуется новым химическим соединением: L-лизина 9-оксоакридинил-10-ацетатом формулы (I) и (II).
摘要:
Disclosed are tricyclic heterocyclic compounds having kinase inhibitory activity, pharmaceutical compositions and kits comprising the compounds, and use of the compounds in the treatment of or in medicaments for the treatment of various diseases and conditions. In particular, disclosed are tricyclic heterocyclic compounds of the formula (I) having CSF-1R (c-FMS kinase) inhibitory activity and their use in the treatment of various diseases and conditions, such as those mediated by CSF-1R, including proliferative or neoplastic diseases and conditions, including cancers, and bone, inflammatory, and autoimmune diseases and conditions.
摘要:
There is provided modulators of Nrf2 protein which comprises a compound which binds at least one of the BTB domain, IVR domain and Kelch domain of Keap1 protein, activating or inhibiting Nrf2. There is also provided pharmaceutical compositions containing the modulators, as well as uses and method of use of the modulators for the treatment of conditions.
摘要:
The present invention relates to new phenylsulfamoyl benzamide derivatives of formula (I), wherein R 1 -R 5 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these compounds, to pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory conditions.
摘要:
The present invention relates to hydrophilic, high quantum yield acridinium compounds. It has been discovered that the placement of electron-donating groups in the acridinium ring system increases the amount of light that is emitted by the corresponding acridinium compound when its chemiluminescence is triggered by alkaline peroxide. More specifically, it has been found that the placement of one or two hydrophilic, alkoxy groups at the C-2 and/or C-7 position of the acridinium ring system of acridinium compounds increases their quantum yield and enhances the aqueous solubility of these compounds. The present hydrophilic, high quantum yield, acridinium compounds are useful chemiluminescent labels for improving the sensitivity of immunoassays.
摘要:
The present invention pertains to acridone and acridine compounds of formula (I), wherein either: (a) K is =O, L is -H, alpha is a single bond, beta is a double bond, gamma is a single bond (acridones); or, (b) K is a 9-substituent, L is absent, alpha is a double bond, beta is a single bond, gamma is a double bond (acridines); and wherein: J is a 2- or 3-substituent; J is a 6- or 7-substituent; J and J are each independently a group of the formula -NHCO(CH2)nNR R , wherein: n is an integer from 1 to 5; and, R and R are independently hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, or R and R , taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 3 to 8 ring atoms; and wherein, when K is a 9-substituent, K is a group of the formula -N(R )Q, wherein: R is an amino substituent and is hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl; and, Q is C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, and is optionally substituted; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit telomerase, to regulate cell prol iferation, and in the treatment of proliferative conditions, such as cancer.
摘要:
The present invention relates to a chemical compound comprising a light emitting moiety precursor (eg. acridine, luciferine) and a precursor of a leaving group (eg. oxazine, anilide), bound to each other by an amide or by an ester bond and characterized in that the leaving group precursor upon oxidation is converted into the leaving group. The invention also relates to compounds additionally comprising a coupling group to the use of such compounds for labeling of biomolecules and more generally to the use of such compounds in chemiluminescence detection procedures.
摘要:
The invention relates to a method for stereochemically controlled production of azacyclic compounds of general formula (I), whereby the substituents have the meaning cited in the description. The invention also relates to intermediate products of this method and to novel azacyclenes.
摘要:
The invention relates to a method for stereochemically controlled production of azacyclic compounds of general formula (I), whereby the substituents have the meaning cited in the description. The invention also relates to intermediate products of this method and to novel azacyclenes.